구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Rovalpituzumab Tesirine |
Overview Company | Stemcentrx |
Overview Modality | ANTIBODY |
Overview Target | Small Cell Lung Cancer |
Overview Indication | Small Cell Lung Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.. Antibody-drug conjugates (ADC) have emerged as an important part of systemic treatment across disease sites. To date, there is no robust pooled prevalence estimate of nausea and vomiting induced by ADCs. Establishing such estimates is essential to determine if ADC-induced nausea and vomiting (ADCI… |
Clinical Safety signal | Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.. Antibody-drug conjugates (ADC) have emerged as an important part of systemic treatment across disease sites. To date, there is no robust pooled prevalence estimate of nausea and vomiting induced by ADCs. Establishing such estimates is essential to determine if ADC-induced nausea and vomiting (ADCI… |
Clinical Selected reported efficacy | ORR 27.6% |
Clinical Reported ORR | 27.6% |
Clinical Result source | ClinicalTrials.gov NCT03026166 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03026166 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Rovalpituzumab Tesirine |
Overview Company | Stemcentrx |
Overview Modality | ANTIBODY |
Overview Target | Small Cell Lung Cancer |
Overview Indication | Small Cell Lung Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.. Antibody-drug conjugates (ADC) have emerged as an important part of systemic treatment across disease sites. To date, there is no robust pooled prevalence estimate of nausea and vomiting induced by ADCs. Establishing such estimates is essential to determine if ADC-induced nausea and vomiting (ADCI… |
Clinical Safety signal | Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.. Antibody-drug conjugates (ADC) have emerged as an important part of systemic treatment across disease sites. To date, there is no robust pooled prevalence estimate of nausea and vomiting induced by ADCs. Establishing such estimates is essential to determine if ADC-induced nausea and vomiting (ADCI… |
Clinical Selected reported efficacy | ORR 27.6% |
Clinical Reported ORR | 27.6% |
Clinical Result source | ClinicalTrials.gov NCT03026166 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03026166 |
추천 비교
추천 비교